Table 5.
Comparison of HRDS scores in patients using different antidepressants in treatment arm-2 and arm-3 from baseline to first, second and third follow-ups (ANOVA).
| Treatment Arm-2 | |||||
|---|---|---|---|---|---|
| Follow-up | HRDS Scores (Mean ± SD) | F-Ratio | p-Value | ||
| Fluoxetine (n = 22) | Escitalopram (n = 18) |
Sertraline (n = 15) | |||
| Baseline | 14.40 ± 1.94 | 14.50 ± 2.17 | 13.73 ± 2.43 | 0.6088 | 0.5477 |
| First | 13.09 ± 2.13 | 13.11 ± 2.11 | 12.4 ± 2.44 | 0.5450 | 0.5831 |
| Second | 11.22 ± 2.04 | 11.44 ± 1.85 | 11.33 ± 1.17 | 0.0734 | 0.9293 |
| Third | 11.00 ± 1.92 | 10.55 ± 1.42 | 10.73 ± 2.01 | 0.3076 | 0.7365 |
| Treatment arm-3 | |||||
| Follow-up | HRDS scores (Mean ± SD) | f-ratio | p-value † | ||
| Fluoxetine (n = 23) | Escitalopram (n = 21) |
Sertraline (n = 11) | |||
| Baseline | 14.34 ± 1.99 | 14.42 ± 2.06 | 14.54 ± 2.77 | 0.0307 | 0.9697 |
| First | 12.26 ± 2.24 | 13.19 ± 1.40 | 12.54 ± 2.54 | 1.1773 | 0.3161 |
| Second | 10.69 ± 1.66 | 11.19 ± 1.03 | 11.36 ± 1.56 | 1.0552 | 0.3554 |
| Third | 9.47 ± 1.59 | 9.95 ±1.16 | 10.18 ± 1.32 | 1.1589 | 0.3217 |
† There was no statistically significant difference observed between the sub-groups.